Humanity Clinical Research Corp — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$205,092	41
2024	Research	$124,760	5
2023	Research	$123,366	6
2022	Research	$193,854	4
2021	Research	$39,990	1
2020	Research	$18,337	2

Breakdown

Who paid Research payments · program years 2020–2025

Otsuka Pharmaceutical Development & Commercialization, Inc. $466,231 17 payments
Janssen Research & Development, LLC $136,208 18 payments
ACADIA Pharmaceuticals Inc $102,960 24 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $142,864 2 payments
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $136,208 18 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $94,997 4 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $75,399 2 payments
Acp-204-012 $74,111 15 payments
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of Avp-786 (Deuterated [D6] Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $57,277 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $35,856 2 payments
Acp-204-013 $28,849 9 payments
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $21,197 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $20,302 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.